Literature DB >> 19814744

Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease.

J-F Rahier1, Y Yazdanpanah, N Viget, S Travis, J-F Colombel.   

Abstract

BACKGROUND: Infection with influenza A (H1N1)v (swine flu) has caused widespread anxiety, among patients who are potentially immunocompromised, such as those being treated for inflammatory bowel disease. AIM: To provide guidance for physicians and their patients on the risk, prevention and management of influenza A (H1N1)v infection.
METHODS: Medline was searched using the following key words: 'swine flu', 'immunosuppression', inflammatory bowel disease', 'recommendations', 'immunization', 'vaccination'. Organizations such as European Centre for Disease Prevention and Control, the Centers for Disease Control and Prevention and the World Health Organization were consulted for recent papers and recommendations regarding immunocompromised patients and influenza A (H1N1)v infection.
RESULTS: Pandemic influenza A (H1N1) virus predominantly affects young patients. Those who are immunocompromised because of underlying disease or treatment are considered at higher risk of complications from influenza A (H1N1). They should be offered prevention (vaccination, postexposure prophylaxis) or treatment with antiviral drugs, if affected. Pneumococcal infection is a complication of influenza infection; therefore, pneumococcal vaccination appears advisable. Seasonal influenza vaccination is also recommended. Withdrawal of immunosuppressive treatment appears advisable during severe active infection if possible.
CONCLUSIONS: Pragmatic advice is the best that can be offered in the current circumstances because of paucity of evidence. Investigation into the impact of influenza A (H1N1)v infection in young people with chronic conditions is needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19814744     DOI: 10.1111/j.1365-2036.2009.04161.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Anti-tumor necrosis factor therapy and influenza: keeping it in perspective.

Authors:  Matt Shale; Markus Czub; Gilaad G Kaplan; Remo Panaccione; Subrata Ghosh
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

2.  Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants.

Authors:  G Andrisani; D Frasca; M Romero; A Armuzzi; C Felice; M Marzo; D Pugliese; A Papa; G Mocci; I De Vitis; G L Rapaccini; B B Blomberg; L Guidi
Journal:  J Crohns Colitis       Date:  2012-06-05       Impact factor: 9.071

3.  AID in aging and autoimmune diseases.

Authors:  Daniela Frasca; Gianluca Andrisani; Alain Diaz; Carla Felice; Luisa Guidi; Bonnie B Blomberg
Journal:  Autoimmunity       Date:  2013-03       Impact factor: 2.815

4.  An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease.

Authors:  Nigel W Crawford; Anthony G Catto-Smith; Mark R Oliver; Donald J S Cameron; Jim P Buttery
Journal:  BMC Gastroenterol       Date:  2011-07-29       Impact factor: 3.067

5.  Immunisation status of children and adolescents with a new diagnosis of inflammatory bowel disease.

Authors:  Timothy Ford; Margie Danchin; Alissa McMinn; Kirsten Perrett; George Alex; Nigel W Crawford
Journal:  BMC Infect Dis       Date:  2022-01-04       Impact factor: 3.090

6.  IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame.

Authors:  Cristina Bezzio; Gionata Fiorino; Davide G Ribaldone; Alessandro Armuzzi; Simone Saibeni
Journal:  Inflamm Bowel Dis       Date:  2022-08-16       Impact factor: 7.290

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.